Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
AR

ARDXStock

Nasdaq Global Market · Healthcare · US

$3.13 last close 2026-11-19
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ARDX's does — no target price to set, unlike a price alert.

Stable Ratio screen, 3 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
3 of 7 pass our financial screen — the standards disagree
Purification 100.00% *HTR non-permissible income <0.01%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 5 timeframes bullish · 47.8% aligned
VWAPPrice holding above VWAP ($3.12)
VolumeRelative volume 2.9× the 20-day average
Momentum10-day rate of change -2.0%

ARDX is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts

Still fetching analyst coverage — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

Momentum (10d)
-2.0%
rate of change
SMC grade
C · 60
47.8% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
<0.01%
Non-permissible income — HTR, from filings (2026-09-30)
C · 60
SMC grade — 47.8% timeframe alignment
-2.0%
Rate of change (10d)

How the status reached this point

Non-compliant · status tracked since Nov 17, 2026

No change to ARDX’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $776.7M as of 2026-11-16. At the 2026-11-19 close it is about $789.3M (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 32.5% (33.0% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 36.2% (36.7% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 33.00% 30.00% Fail(3.0pp over)
Interest-bearing investments 36.74% 30.00% Fail(6.7pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Usmani Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 43.63% 33.00% Fail(10.6pp over)
Interest-bearing investments 48.57% 33.00% Fail(15.6pp over)
Non-liquid assets 35.53% at least 20.00% Pass(15.5pp above the floor)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI Fail 1 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 43.63% 33.33% Fail(10.3pp over)
Cash + interest-bearing securities 48.57% 33.33% Fail(15.2pp over)
Accounts receivable 64.47% 33.33% Fail(31.1pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
FTSE Fail 1 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 42.95% 33.33% Fail(9.6pp over)
Cash + interest-bearing securities 48.57% 33.33% Fail(15.2pp over)
Accounts receivable 64.47% 50.00% Fail(14.5pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 20.41% 33.00% Pass(12.6pp buffer)
Cash + interest-bearing securities 22.72% 33.00% Pass(10.3pp buffer)
Accounts receivable 7.44% 33.00% Pass(25.6pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 18.90% 33.00% Pass(14.1pp buffer)
Cash + interest-bearing securities 21.04% 49.00% Pass(28.0pp buffer)
Accounts receivable 6.89% 49.00% Pass(42.1pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 18.90% 33.33% Pass(14.4pp buffer)
Cash + interest-bearing securities 21.04% 33.33% Pass(12.3pp buffer)
Accounts receivable 27.93% 49.00% Pass(21.1pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 5.0pts
Usmani (% of total assets)non permissible income ratio 5.0pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 5.0pts
MSCI Islamic Index (% of total assets)receivables ratio 31.1pts
Usmani (% of total assets)investments ratio 15.6pts
MSCI Islamic Index (% of total assets)cash and interest ratio 15.2pts

The numbers the ratios are built from

Read from ARDX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $407.3M 2026-09-30 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $252.4M 2026-09-30 LongTermDebt
Cash and interest-bearing securitiesCash, equivalents and marketable securities $285.3M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total assetsBalance sheet total $587.5M 2026-09-30 Assets
Market capDenominator for AAOIFI $776.7M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $1.4B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $1.3B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2026-09-30 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2026-09-30. Screened 2026-11-16.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$587.5M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$252.4M
    LongTermDebt · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$285.3M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent · balance sheet as of 2026-09-30
  • Receivables$93.4M
    AccountsReceivableNetCurrent · balance sheet as of 2026-09-30
  • Revenue$407.3M
    RevenueFromContractWithCustomerExcludingAssessedTax · income statement as of 2026-09-30
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2026-09-30
  • Market cap$776.7M
    Market-data quote at screen time, 2026-11-16 · not a filing figure, so no link

What changed, and when

Verdict history for ARDX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-16 Unverified → Pass filing re-screen
  • 2026-11-16 Unverified → Fail filing re-screen
  • 2026-11-09 Compliant → Non Compliant watchlist re-scan

Tracked since 2026-09-07.

Revenue by business segment

How ARDX’s $407.3M of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.

Fiscal year ended 2025-12-31
SegmentShareRevenue
IBSRELA 67.3% $274.2M
XPHOZAH 25.4% $103.6M
Product supply revenue 3.9% $15.9M
Non-cash royalty revenue related to the sale of future royalties 2.1% $8.5M
Licensing revenue 1.2% $5.1M

These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.

Source: 10-K filed 2026-02-19 (accession 0001437402-26-000013), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.

What would change the status

The headline verdict is the majority of the decided ratio standards — 3 pass and 4 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-16.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio is $256.3M debt (operating leases included, as the screen counts it) over a market cap of $776.7M (as of 2026-11-16), 33.0% against a 30% line.

At the 2026-11-19 close the market cap is about $789.3M (the stored cap moved by the share price since), so this ratio would read 32.5%; the line is +8% from there. The published status changes only when the company is re-screened.

It would pass if the market cap rose above $854.5M (+10%), about $3.40 a share against $3.09 implied by the screen's own figures.

AAOIFI would then fail; the majority verdict would stay Not compliant (3 of 7 decided standards passing).

At the screen's market cap, it would take $23.3M less debt to clear the line.

AAOIFI would then fail; the majority verdict would stay Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).

AAOIFI's investments ratio is $285.3M cash and interest-bearing investments over a market cap of $776.7M (as of 2026-11-16), 36.7% against a 30% line.

At the 2026-11-19 close the market cap is about $789.3M (the stored cap moved by the share price since), so this ratio would read 36.2%; the line is +21% from there. The published status changes only when the company is re-screened.

It would pass if the market cap rose above $951.1M (+22%), about $3.78 a share against $3.09 implied by the screen's own figures.

AAOIFI would then pass; the majority verdict would stay Not compliant (4 of 7 decided standards passing), because it is held (Zoya rates it not compliant, and our screen does not overrule another screener's doubt).

At the screen's market cap, it would take $52.3M less cash and interest-bearing investments to clear the line.

AAOIFI would then fail; the majority verdict would stay Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold ARDX

4 of the 202 funds whose filed holdings we currently hold own ARDX shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ARDX.

You may already own it

Widely held U.S. index funds. If you own one, you own ARDX through it. None of them is a Shariah fund; the last column is our look-through of each.

FundARDX in fundFund compliant by weight
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00% 54%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
SCHB Schwab U.S. Broad Market ETF 0.00% 53%
Other funds
FundARDX in fundFund compliant by weight
ISCV iShares Morningstar Small-Cap Value ETF 0.02% 21%

Sorted by ARDX’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ARDX once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding ARDX
InvestorFirmPositionWeightAs of
Israel Englander Millennium Management $46M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $7M 0.0% 2026-09-30
John Hussman Hussman Strategic Advisors $1M 0.3% 2026-09-30
Peter Brown Renaissance Technologies $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

7.996.715.434.162.882025-11-192026-05-222026-11-19

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
2.88
S2
2.98
S1
3.05
PIVOT
3.15
R1
3.22
R2
3.33
R3
3.40

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
3.06 – 3.78
±10.45% from 3.42, made 2026-09-27 · resolves 2026-10-04
STRONG SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

BUY
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSELL
5 buy · 0 neutral · 7 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)50.50NEUTRAL
Stochastic %K (14)57.38NEUTRAL
CCI (20)90.40NEUTRAL
Williams %R (14)-42.62NEUTRAL
MACD (12,26,9)0.03BUY
ROC (10)5.35BUY
Momentum (10)0.16BUY
EMA (10)3.10BUY
SMA (10)3.07BUY
EMA (20)3.11BUY
SMA (20)3.07BUY
EMA (30)3.16SELL
SMA (30)3.10BUY
EMA (50)3.33SELL
SMA (50)3.23SELL
EMA (100)3.86SELL
SMA (100)3.88SELL
EMA (200)4.78SELL
SMA (200)5.01SELL

About ARDX

Healthcare · Biotechnology

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ardelyx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 64
⏰ 4H RANGING 43
🕐 1H RANGING 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-2.0%
Rate of change (10d)
2.9×
Volume vs its 20-day average
-0.03
MACD (no fresh cross)
$3.14
Volume POC (today)
$3.12 – $3.16
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

CLUSTER SELL   0 buys · 21 sells

Recent: RAAB MICHAEL sold 1663357 sh @ $3.86 (2026-08-21); RAAB MICHAEL sold 1647381 sh @ $3.86 (2026-08-21); RAAB MICHAEL sold 1638970 sh @ $3.86 (2026-08-21)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.